128244-01-9

Usage

Uses

Used in Medicinal Chemistry:
1-BENZYL-1,7-DIAZASPIRO[4,4]NONANE is used as a building block for the synthesis of various bioactive compounds due to its unique spirocyclic structure and potential to contribute to the development of new pharmaceuticals.
Used in Antibacterial Applications:
1-BENZYL-1,7-DIAZASPIRO[4,4]NONANE is used as an antibacterial agent for its demonstrated properties against certain bacterial strains, offering a potential solution in the fight against bacterial infections.
Used in Antifungal Applications:
1-BENZYL-1,7-DIAZASPIRO[4,4]NONANE is used as an antifungal agent, leveraging its properties to combat fungal infections, which is crucial in various medical and agricultural settings.
Used in Anticancer Research:
1-BENZYL-1,7-DIAZASPIRO[4,4]NONANE derivatives are used as anti-cancer agents in research settings, where they are studied for their potential to inhibit cancer cell growth and contribute to cancer treatment strategies.
Used in Synthetic Chemistry:
1-BENZYL-1,7-DIAZASPIRO[4,4]NONANE is used as a target for synthetic chemistry research, where its unique structure is explored for the creation of novel compounds and materials with specific properties and applications.

InChI:InChI=1/C14H20N2/c1-2-5-13(6-3-1)11-16-10-4-7-14(16)8-9-15-12-14/h1-3,5-6,15H,4,7-12H2

Upstream product

• 128244-00-8 1-benzoyl-1,7-diazaspiro<4.4>nonan-6-one 
• 5493-38-9 N-benzoyl-L-proline methyl ester 
• 98-88-4 benzoyl chloride 
• 646055-59-6 6-benzyl-2,6-diazaspiro[4.4]nonan-1-one 
• 128243-98-1 methyl 1-benzoyl-2-(nitrilomethyl)pyrrolidine-2-carboxylate 
• 128243-99-2 2-(2-Amino-ethyl)-1-benzoyl-pyrrolidine-2-carboxylic acid methyl ester 
• 5874-58-8 N-(benzoyl)-L-proline 

Downstream Products

• 646055-60-9 1-benzyl-7-(3-pyridinyl)-1,7-diazaspiro[4.4]nonane 
• 646055-62-1 tert-butyl 6-benzyl-2,6-diazaspiro [4.4]nonane-2-carboxylate 
• 1148044-32-9 C₁₆H₁₉F₃N₂O 
• 646055-72-3 1-benzyl-7-(5-phenoxy-3-pyridyl)-1,7-diazaspiro[4.4]nonane 

Relevant academic research and scientific papers

SUBSTITUTED 2-HYDROGEN-PYRAZOLE DERIVATIVE SERVING AS ANTICANCER DRUG

Disclosed is a substituted 2H-pyrazole derivative serving as a selective CDK4/6 inhibitor. Specifically, disclosed is a compound of formula (I) or a pharmaceutically acceptable salt thereof which serves as a selective CDK4/6 inhibitor.

PREPARATION AND ENANTIOMERIC SEPARATION OF 7-(3-PYRIDINYL)-1,7-DIAZASPIRO[4.4] NONANE AND NOVEL SALT FORMS OF THE RACEMATE AND ENANTIOMERS

A novel scalable synthesis for the preparation of 7-(3- pyridinyI)- 1,7- diazaspiro[4.4)nonane has been developed, and7-(3-pyridinyl)-1,7-diazaspiro[4.4]nonane salts have been formed with succinic acid and oxalic acid. Additionally, 7-(3-pyridinyl)-1,7- diazaspiro[4.4]nonane has been separated into its stereoisomers via resolution with L and D di-p-toluoyltartaric acids, giving (R)- and (S)-7-(3-pyridinyl)-1,7-diazaspiro[4.4]nonane of high enantiomeric purity. Numerous solid salts of the resulting (R)- and (S)-7-(3-pyridinyl)-1,7- diazaspiro[4.4}nonane have been prepared. Methods for the preparation of the racemic and enantiomeric salts, pharmaceutical compositions comprising such salts, and uses thereof are disclosed. The salts can be administered to patients susceptible to or suffering from conditions and disorders, such as central nervous system disorders, to treat and/or prevent such disorders.

THE USE OF N-ARYL DIAZASPIRACYCLIC COMPOUNDS IN THE TREATMENT OF ADDICTION

Compounds, compositions and methods for treating drug addiction, nicotine addiction, and/or obesity are disclosed. The compounds are N-aryl diazaspirocyclic compounds, bridged analogs of N-heteraryl diazaspirocyclic compounds, or prodrugs or metabolites of these compounds. The aryl group can be a five- or six-membered heterocyclic ring (heteroaryl). The compounds are effective at inhibiting dopamine production and/or secretion, and accordingly are effective at inhibiting the physiological "reward" process that is associated with ingestion of nicotine and/or illicit drugs. The compounds and compositions can be administered in effective amounts to inhibit dopamine release, wihout resulting in appreciable adverse side effects (e.g., side effects such as significant increases in blood pressure and heart rate, significant negative effects upon the gastro-intestinal tract, and significant effects upon skeletal muscle).

Quinolone Antibacterial Agents Substituted at the 7-Position with Spiroamines. Synthesis and Structure-Activity Relationships

A series of fluoroquinolone antibacterials having the 7-position (10-position of pyridobenzoxazines) substituted with 2,7-diazaspirononane (4b), 1,7-diazaspirononane (5a), or 2,8-diazaspiroundecane (6b) was prepared, and their biological activities were compared with piperazine and pyrrolidine substituted analogues.Most exhibited potent Gram-positive and Gram-negative activity, especially when side chain 4b was N-alkylated.